DXCM (DexCom) Stock Based Compensation: $169 Mil (TTM As of Mar. 2026)


DXCM DexCom Inc DXCM
90 GF Score
Price $68.86
GF Value $103.81
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is DexCom Stock Based Compensation?

DexCom DXCM +2.24% 90 Stock Based Compensation is $169 Mil as of Mar. 2026. GuruFocus rates DXCM with a GF Score™ of 90/100 and a GF Value™ of $103.81 (Significantly Undervalued). The stock has 3 warning signs investors should review.

DexCom's Stock Based Compensation for the three months ended in Mar. 2026 was $43 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $169 Mil.

DexCom Stock Based Compensation Related Terms

DexCom Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for DexCom's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DexCom Stock Based Compensation Chart

DexCom Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 113.40 126.50 150.80 170.40 159.60

DexCom Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.20 45.30 45.10 35.00 43.30
DXCM
90GF Score
DexCom Inc DXCM
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DexCom Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $169 Mil.

What does a Stock Based Compensation of $169 Mil mean?
DexCom (DXCM) has a Stock Based Compensation of $169 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for DexCom and its competitors.
Is DexCom's Stock Based Compensation too high?
DexCom's current Stock Based Compensation is $169 Mil. Overall, DexCom has a GF Score™ of 90/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DexCom's Stock Based Compensation compare to GEHC and STE?
DexCom's Stock Based Compensation of $169 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Devices & Instruments company?
A good Stock Based Compensation depends on the Medical Devices & Instruments industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for DexCom and its competitors. DexCom's current Stock Based Compensation is $169 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexCom stock overvalued right now?
Based on GuruFocus' analysis, DexCom (DXCM) is currently considered Significantly Undervalued. The stock's GF Value™ is $103.81, compared to a current price of $68.86 — trading 33.7% below its estimated fair value. The current Stock Based Compensation is $169 Mil. DexCom's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For DexCom (DXCM), the current Stock Based Compensation is $169 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DexCom (DXCM) Overvalued in 2026?

Based on GuruFocus' analysis, DexCom stock appears to be undervalued. The current stock price of $68.86 is trading 33.7% below its estimated GF Value™ of $103.81. GuruFocus considers DexCom to be Significantly Undervalued.

Key valuation signals for DXCM:

  • Stock Based Compensation: $169 Mil
  • GF Value™: $103.81 vs. price of $68.86 (33.7% below fair value)
  • GF Score™: 90/100 with 3 warning signs

No single metric tells the full story. See the DXCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DexCom Business Description

Address 6340 Sequence Drive, San Diego, CA, USA, 92121
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
90GF Score

Get the complete analysis for DXCM

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$68.86
Price
$103.81
GF Value